Iconic Therapeutics is a clinical stage biopharmaceutical company dedicated to translating scientific insight into breakthrough medicines. Our deep understanding of the role of Tissue Factor (TF) in angiogenesis, inflammation, and metastasis has led us to develop a new approach to retinal disease and cancer. Our lead product candidate, ICON-1, is a novel immune-conjugate fusion protein that works with the body’s immune system to address the root causes of inflammation and angiogenesis together, potentially altering the course of leading causes of blindness.

Iconic has completed a Phase 1 clinical trial in wet AMD and is conducting a Phase 2 study to assess the biologic activity and pharmacodynamic effect in newly diagnosed AMD patients and a Phase 1 study in Ocular Melanoma investigating the ICON family of proteins in cancer and have initiated a research program in solid tumors.

The company’s broad intellectual property portfolio was exclusively licensed from Yale University, one of the first institutions where TF was cloned and characterized.